And if the Research Community Does in Fact Find a Viable Treatment for Obesity?
We report the discovery of a new monomeric peptide that reduces body weight and diabetic complications in rodent models of obesity by acting as an agonist at three key metabolically-related peptide hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon receptors. Such balanced unimolecular triple agonism proved superior to any existing dual coagonists and best-in-class monoagonists to reduce body weight, enhance glycemic control and reverse hepatic steatosis in relevant rodent models. We demonstrate that these individual constituent activities harmonize to govern the overall metabolic efficacy, which predominantly results from synergistic glucagon action to increase energy expenditure, GLP-1 action to reduce caloric intake and improve glucose control, and GIP action to potentiate the incretin effect and buffer against the diabetogenic effect of inherent glucagon activity.
Source: Fight Aging! - Category: Research Authors: Reason Tags: Medicine, Biotech, Research Source Type: blogs
More News: Biotechnology | Brain | Burns | Diabetes | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Expenditures | Funding | Gastroenterology | Health | Health Medicine & Bioethics Commentators | Hormones | Incretin Therapy | Insulin | Liver | Neurology | Nutrition | Obesity | Pancreas | Research | Rural Health | Science | Urology & Nephrology